Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases.

Dynamic histone lysine methylation involves the activities of modifying enzymes (writers), enzymes removing modifications (erasers), and readers of the histone code. One common feature of these activities is the recognition of lysines in methylated and unmethylated states, whether they are substrates, reaction products, or binding partners. We applied the concept of adding a lysine mimic to an established inhibitor (BIX-01294) of histone H3 lysine 9 methyltransferases G9a and G9a-like protein by including a 5-aminopentyloxy moiety, which is inserted into the target lysine-binding channel and becomes methylated by G9a-like protein, albeit slowly. The compound enhances its potency in vitro and reduces cell toxicity in vivo. We suggest that adding a lysine or methyl-lysine mimic should be considered in the design of small-molecule inhibitors for other methyl-lysine writers, erasers, and readers.

[1]  Cristiano Ruch Werneck Guimarães,et al.  MM-GB/SA Rescoring of Docking Poses in Structure-Based Lead Optimization , 2008, J. Chem. Inf. Model..

[2]  P. Cole,et al.  Chemical probes for histone-modifying enzymes. , 2008, Nature chemical biology.

[3]  Paul Greengard,et al.  Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity , 2010, Science.

[4]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[5]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[6]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[7]  Y Ikawa,et al.  A novel ES cell line, TT2, with high germline-differentiating potency. , 1993, Analytical biochemistry.

[8]  R. Smits,et al.  Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach. , 2008, Journal of medicinal chemistry.

[9]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[10]  D. Reinberg,et al.  Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins*S⃞ , 2009, Journal of Biological Chemistry.

[11]  Robert A. Copeland,et al.  Protein methyltransferases as a target class for drug discovery , 2009, Nature Reviews Drug Discovery.

[12]  D. Langley,et al.  O-Debenzylation of a Pyrrolo[2,1-c][1,4]benzodiazepine in the Presence of a Carbinolamine Functionality: Synthesis of DC-81 , 1990 .

[13]  C. Song,et al.  A modified synthesis of iodoazidoaryl prazosin. , 2002, The Journal of organic chemistry.

[14]  Anton Simeonov,et al.  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. , 2009, Journal of medicinal chemistry.

[15]  M. Hsu,et al.  An efficient synthesis of pyrrolo[2,1-c][1,4]benzodiazepine. Synthesis of the antibiotic DC-81. , 2001, The Journal of organic chemistry.

[16]  Sascha Karberg Switching on Epigenetic Therapy , 2009, Cell.

[17]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[18]  Valérie Campagna-Slater,et al.  Structural Biology of Human H3K9 Methyltransferases , 2010, PloS one.